Merck的RSV抗体在幼儿身上显示出显著效果,支持扩大保护和林业发展局的批准。 Merck's RSV antibody showed strong results in young children, supporting extended protection and FDA approval.

Merck宣布了对两岁以下儿童的RSV单克隆抗体Enflonsia(clesrovimab)进行SMART试验的第3阶段的积极结果,显示持续的安全性和有效血清水平支持第二剂剂量,将保护范围扩大到第二个RSV季节。 Merck announced positive Phase 3 SMART trial results for its RSV monoclonal antibody Enflonsia (clesrovimab) in children under two, showing sustained safety and effective serum levels supporting a second dose for extended protection into a second RSV season. 这些数据与之前的发现一起,支持了FDA在2025年批准在婴儿的第一个RSV季节使用. The data, along with prior findings, underpinned the FDA’s 2025 approval for use in infants during their first RSV season. GSK报告说,其RSV疫苗AREXVY在大约五个月后对住院有效率为75.6%,早期有心血管治疗迹象。 GSK reported its RSV vaccine AREXVY was 75.6% effective against hospitalization after about five months, with early signs of cardiovascular benefit. Merck的股票比去年上升42%, 与持有买家评级的分析师进行接近52周高的交易。 Merck’s stock rose 42% over the past year, trading near its 52-week high with analysts maintaining a Buy rating.